|Bid||15.50 x 1400|
|Ask||16.20 x 1800|
|Day's Range||15.99 - 16.50|
|52 Week Range||15.40 - 26.75|
|Beta (5Y Monthly)||1.49|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Nektar Therapeutics (NASDAQ:NKTR) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […]
Nektar Therapeutics ( NASDAQ:NKTR ) has not performed well recently and CEO Howard Robin will probably need to up their...